11 analysts have expressed a variety of opinions on Glaukos (NYSE:GKOS) over the past quarter, offering a diverse set of opinions from bullish to bearish.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $156.45, a high estimate of $185.00, and a low estimate of $120.00. Witnessing a positive shift, the current average has risen by 10.26% from the previous average price target of $141.89.

Exploring Analyst Ratings: An In-Depth Overview

A comprehensive examination of how financial experts perceive Glaukos is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Glaukos's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Glaukos analyst ratings.

All You Need to Know About Glaukos

Glaukos: A Financial Overview

Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.

Revenue Growth: Glaukos's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 23.86%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: Glaukos's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -22.15%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Glaukos's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -3.21%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): Glaukos's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -2.32%, the company may face hurdles in achieving optimal financial performance.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.24.

The Basics of Analyst Ratings

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.